Oral SERDs for Estrogen Receptor-Positive MBC - Metastatic Breast Cancer Trial Talk

Research News

Selective estrogen receptor degraders (SERDs) are a type of anti-hormone therapy used to treat metastatic ER-positive breast cancer. Oral SERDs are taken by mouth instead of given by injection. SERDs attach to the estrogen receptor (ER), prevent ER from working, and eventually lead to ER degradation (the breakdown of estrogen receptors). 

Currently, fulvestrant (Faslodex®) is the only SERD approved by the FDA for treating MBC, but fulvestrant is not available in oral form. Many new oral SERDs are being studied in clinical trials for treating MBC that has progressed on tamoxifen or an aromatase inhibitor.

Read below to understand how oral SERDs work and learn about current research, potential future research, and uses of oral SERDs.

What Are Oral SERDs and How Do They Work?
Current Research and Future Directions of Oral SERDs
Clinical Trials for Oral SERDs



for past articles or specific information.